Junevity
2 known investors
Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.
Founders & leadership
JH
John HoekmanCo-founder & CEO
JS
Janine SengstackCo-founder & CSO
RC
Rob CahillCo-founder, COO & CBO
HL
Hao LiCo-founder & UCSF Professor
Investors · 2
.jpeg){kind=logo}
Funding
SEC filings, press & company announcements$20M disclosed across 1 of 3 rounds · 2025
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 1
by search overlapCompanies competing with Junevity for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Junevity do?
- Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.
- Who founded Junevity?
- Junevity was founded by John Hoekman, Janine Sengstack, Rob Cahill, Hao Li.
- Who are Junevity's investors?
- Junevity's investors include Goldcrest Capital, Type One Ventures.
- How much funding has Junevity raised?
- Junevity has disclosed $20M raised across 1 of its 3 known rounds.